ArticleIn vivo (Athens, Greece)
Investigation of MicroRNA-30d-5p Expression and SOCS3 Levels in Non-small Cell Lung Cancer.
Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimNon-small cell lung cancer (NSCLC) accounts for most lung cancer cases and has high mortality, especially in advanced stages. MicroRNAs (miRNAs) and immunoregulatory genes such as suppressor of cytokine signaling 3 (SOCS3) play critical roles in cancer progression and immune evasion. miR-30d-5p is known to act as a tumor suppressor by down-regulating oncogenic pathways, while SOCS3 modulates immune responses and tumor microenvironment interactions. This study aimed to evaluate the clinical relevance of circulating miR-30d-5p and serum SOCS3 protein levels in patients with NSCLC MATERIALS AND
methodsSerum samples were collected from 35 patients with NSCLC and 26 healthy individuals. miR-30d-5p expression was measured using RT-qPCR, and SOCS3 protein levels were determined using ELISA. Statistical comparisons were performed, and diagnostic performance was evaluated using Receiver Operating Characteristic (ROC) analysis. The correlation between SOCS3 and miR-30d-5p was assessed with Spearman's rank test.
resultsSOCS3 levels were significantly elevated in patients with NSCLC (120.84±117.62 pg/ml) compared to controls (16.88±11.91 pg/ml,
conclusionIncreased SOCS3 and decreased miR-30d-5p expression were observed in patients with NSCLC, indicating their involvement in tumor progression and immune disruption. The inverse correlation between these biomarkers suggests a regulatory interaction that may influence the JAK/STAT signaling pathway. These findings highlight the diagnostic and therapeutic potential of targeting the miR-30d-5p/SOCS3 axis in NSCLC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.